As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.
Oncology Vol 31 No 3
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
3
Outlining Exercise as a “Biologically Interventional Therapy” for Cancer
4
Navigating The Dynamic Landscape of Stem Cell Transplantation
5